OncoPharm 9 22
Sep 22, 2022
Celebrating 9/22 Day, the podcast dives into the crucial history of the 9;22 translocation in hematological oncology. John details the groundbreaking discovery of a shortened chromosome 22 and Janet Rowley's pivotal research linking it to CML. Listeners learn about the BCR-ABL fusion genes and their clinical implications, including the transformative role of imatinib in cancer treatment. The discussion wraps up with insights on how this genetic understanding reshaped our approach to cancer.
AI Snips
Chapters
Transcript
Episode notes
Philadelphia Chromosome Changed Cancer Thinking
- The Philadelphia chromosome began as an observation of a shortened chromosome 22 in CML patients.
- That simple cytogenetic finding reshaped how we view cancer as a genetic disease.
Hungerford And Nowell's Early Discovery
- John recounts David Hungerford and Peter Nowell's 1959 discovery at Fox Chase identifying the short chromosome 22.
- Their junior status delayed acceptance despite the clear chromosomal abnormality in CML patients.
Rowley Revealed The 9;22 Translocation
- Janet Rowley's 1973 Nature paper showed the abnormality was a translocation between chromosomes 9 and 22.
- Her work revealed that material from chromosome 9 was swapped onto 22, producing the translocation 9;22.